The Huntington's Disease Society of America's Indiana Chapter will host a one-mile walk in Zionsville on Saturday.

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

With Indiana's Election Day approaching Nov. 8 and early voting underway, several listeners are curious about voter rights.

West Lafayette Mayor John Dennis announced Thursday he has been diagnosed with early-onset Alzheimer's disease.

The National Institutes of Health has awarded $217 million to fund research at Indiana University School of Medicine in the current fiscal year. This will fund more research on Alzheimer's and community outreach projects.

An aging population is producing a growing number of Alzheimer’s and dementia diagnoses in the state. These increasing numbers have prompted first year students at the IU School of Medicine in Indianapolis and Fort Wayne to attend training seminars for caring for patients with these diseases.

The announcement comes a few weeks after the Food and Drug Administration approved a treatment from rival Biogen despite warnings from the agency's independent advisers that it hasn't been shown to help slow the brain-destroying disease.

Alzheimer's disease affects more than 5 million Americans, but the disease is still a mystery to scientists and doctors.

In Indiana, the number of patients with Alzheimer's is expected to grow by nearly 20 percent in the next five years, there are a number of new programs and opportunities for people to use music to support memory.

The Indiana University School of Medicine will partner with Purdue University to develop research tools and technologies to identify new treatment options.